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Today, farmers and the environment are benefiting from the first generation of
genetically engineered (GE) crops. The biotechnology industry and academics
trumpet the next generation of such crops in terms of greater nutritive value,
and new sources of pharmaceuticals, antibodies, industrial enzymes, etc.
If␣ those crops are commercialized, is the current regulatory structure in the
United States up to the task of ensuring that they are safe for humans and
the␣ environment? In this paper, I analyze the ability of the regulatory system
to␣ adequately regulate the next generation of products from agricultural
biotechnology. Without additional legal authority and stronger oversight,
the␣ regulatory system cannot ensure that only GE crops that are safe for
humans and the environment will be commercialized.
WHAT DOES THE FUTURE HOLD?
Virtually every week there is media coverage of new applications for agricul-
tural biotechnology. New genes are being added to crops to make food more
nutritious. For example, in the past year, the press has reported on the
following potential products:
• Two genes from daffodil and one from a bacterium have been inserted into
rice. “Golden” rice produces beta-carotene, which the human body
converts to vitamin A.
• At University of California at Davis, scientists have transformed rice with
the gene for the human breast-milk protein lactoferrin, with the objective
of fighting infections.
• In Australia, a gene for a protein present in cows’ milk has been inserted
into calves to enable production of higher-protein, more nutritious milk.
• Researchers are increasing the anti-oxidant properties of tomatoes by
engineering them to synthesize more lycopene and increased levels of
lutein (known to help fight eye disease).
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Progress is being made in inducing crops to serve as “factories” for biologically
active molecules in a cost-efficient and renewable manner. For example:
• Prodigene has engineered corn to produce avidin and trypsin. Avidin,
naturally found in egg whites, is used in medical and biochemical
diagnostics. Trypsin is an industrial enzyme used in drug production.
• Epicyte is currently engineering plants to synthesize a topically applied
antibody that prevents the transmission of herpes simplex virus.
• Hiridin, a human anticoagulant protein, produced in transgenic canola, is
available commercially in Canada.
• Corn has been genetically engineered to make an antigenic protein from
the surface of the human immunodeficiency virus (HIV), which causes
AIDS. Tests in animals are in progress for immune responses after ingestion
of the transformed corn. Bananas and carrots are also being engineered to
produce vaccines.
Those potential products, and many others, provide hope that the next
generation of GE crops—fruits, vegetables, and grains—will benefit consumers,
both in developed and developing countries, as nutritious and healthful foods
and as new sources of pharmaceutical and industrial molecules.
IS THE REGULATORY STRUCTURE UP TO THE TASK OF REGULATING
NEW USES OF AGRICULTURAL BIOTECHNOLOGY?
Currently, agricultural biotechnology is regulated to protect human health and
the environment. Is the current federal regulatory system up to the task of
thoroughly assessing how safe the next generation of GE crops will be for
humans and the environment? A review of the regulatory system’s treatment of
the first generation of GE crops reveals weaknesses and gaps in the current
system and problems that will arise when regulating future crops. New
statutory authority and stronger oversight are needed to ensure that only
commercial products that are safe for humans and the environment will be
marketed. 1
ENSURING THAT GE CROPS ARE SAFE TO EAT
Consumers want assurances that the foods they eat are safe. Thus, the Food
and␣ Drug Administration (FDA) should ensure the safety of biotech foods.
The␣ FDA’s current regulatory system, however, does not adequately ensure
that␣ only safe GE crops are marketed.
Current Regulation of Biotech Foods Currently, FDA does not formally approve
any GE crops as safe to eat. The FDA has the authority to approve new food
1Drugs and vaccines produced by the next generation of GE crops will be regulated similarly to their
conventionally produced counterparts. Discussion of those regulatory issues is not included here.
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additives, but says that the GE crops developed so far do not fall within that
category. Instead, FDA has determined that GE crops are similar to convention-
ally bred crops and typically fall into the category of “generally recognized as
safe” (GRAS) foods. FDA’s policy does allow a GE crop to be treated as a food
additive requiring mandatory approval if that crop raises a food-safety concern.
However, to date, FDA has not determined that any GE crop should be
considered a food additive, and it is unclear if any future crop will be so
considered. Both FDA and the biotech industry will strongly resist putting GE
foods through the food-additive process, which is perceived as time-consuming
and burdensome.
To oversee any potential food-safety concerns that might exist for a GE crop,
FDA adopted a voluntary consultation process to review safety data provided
by␣ companies to ensure compliance with existing laws. In that process, the
company provides summary information about the safety of its product to FDA,
which, in turn, provides informal advice about the adequacy of the tests
conducted by the company. In conducting its scientific safety assessment, the
company provides information to show that the GE variety is “substantially
equivalent”, i.e. as safe as its conventionally bred counterpart. To date, all
commercialized GE crops have proceeded through the voluntary consultation
process before marketing.
Problems with FDA Current Biotechnology Policy There are numerous problems
with FDA’s current policy for GE crops. First, the consultation process is
voluntary. There is no legal obligation requiring a company to provide a safety
assessment to FDA and no consequences to the company that does not
voluntarily consult. Second, the consultation process is developer-driven
instead of FDA-driven. The biotechnology company decides what safety tests
to␣ conduct and what data to submit, because the company’s obligation is to
satisfy itself that the product is safe rather than to prove safety to FDA. This
process provides FDA with limited ability to require specific tests or mandate
specific data. Third, FDA’s food-safety analysis is not comprehensive. Their
guidance states that the consultation process is “not a comprehensive scientific
review of the data generated by the developer.” Fourth, and most importantly,
FDA does not determine if the product is safe. The voluntary consultation
process culminates with FDA stating that it has “no further questions . . . at
this␣ time” rather than stating that the product is safe to eat.
Although no human-health problems with GE crops have been detected, the
voluntary consultation process is not the most effective way to protect the
consumer and engender confidence. In the coming years, the scientific safety
issues raised by more-complex GE crops (nutritionally enhanced, engineered
with new metabolic pathways) cannot be adequately assessed with the current
industry-driven process.
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FDA’s Proposed Mandatory Notification Rule In January 2001, the FDA proposed
regulations that would mandate notification before a GE food is marketed.
Although that proposal improves upon the current process by mandating
agency review and by increasing transparency, it does not change the agency’s
scientific review nor will it result in an official determination of safety. Under
the mandatory notification, FDA still will not respond with an affirmation that
the food is safe to eat. Also, if a developer markets a GE food without notifying
FDA, FDA still must prove the food is adulterated before it can be removed
from commerce.
How Will the Current System Treat the Second Generation of Biotech Foods?
If␣ high-lycopene tomato makes its way to the marketplace, will FDA’s current
regulatory policy treat it any differently from the first generation of herbicide-
resistant and pesticide-producing crops? The answer is no. It is unlikely that
FDA will treat the second generation of GE crops as products that contain
additives since the gene products in high-lycopene tomato or rice engineered
to␣ contain human breast-milk protein are already present in the normal human
diet. Thus, the only food-safety assessment those products will receive is the
less-than-comprehensive voluntary-consultation process. Those products will
have to abide by the mandatory notification process, but only if FDA finalizes
that proposed rule. The FDA has stated that it will not make a decision on its
proposed rule before fiscal year 2003, and, if promulgated, no one knows what
form the final rule will take.
A Proposal for a Mandatory Approval Process The FDA should establish a new
mandatory approval process for GE crops, unrelated to the current food-
additive process. It should promulgate regulations that establish testing and
data requirements based on advice from a National Academy of Sciences panel
charged with determining what scientific information is needed to assess food-
safety concerns regarding such crops. The approval process should have time
limits so that each application receives a determination within a reasonable
interval. In addition, the mandatory approval process should ban any GE food
with a new allergen as well as prohibit approvals for crops intended for animal
feed but not human consumption. If new legislation is needed so that FDA can
implement an approval process, Congress should pass such legislation.
A mandatory pre-market approval process at FDA for biotech foods would
have numerous advantages over the current system. First, formal approval
would provide an independent check on industry’s safety determination. FDA
would share responsibility for the safety determination and would help prevent
food-safety mistakes. Second, it would eliminate the gap in the regulatory
system that allows some biotech foods, but not others, to be marketed without
pre-approval. Currently, transgenic animals require pre-market approval by
FDA and pesticidal plants require pre-market approval by the Environmental
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Protection Agency, yet non-pesticidal transgenic plants are subject only to
FDA’s␣ voluntary consultation process. Third, a mandatory process need not be
more burdensome to applicants than the current voluntary procedure. The
industry states that it already conducts all reasonable and necessary tests to
ensure safe products, so there is little likelihood that FDA would require
significant new testing. Fourth, a mandatory approval process would make
the␣ regulatory system in the United States similar to those in Canada and
Europe, where biotech foods must be affirmatively approved before marketing.
Finally, a␣ food-safety determination by FDA would go a long way to improving
consumer confidence and public perception of the safety and acceptability of
biotech foods. Consumers would be much more comfortable with FDA’s
determination that a food is safe to eat than with Monsanto or Dupont’s
in-house determination.
In conclusion, the benefits of a properly constructed mandatory approval
process at FDA would be significant and the burden for industry need not be
much greater than the current voluntary consultation process. It is unclear why
industry is against a process that would provide an independent verification of
a product’s safety and thus sway the skeptical consumer. Therefore, producers
of new GE crops should embrace sensible legislation to require a mandatory
approval, such as Senator Durbin’s Genetically Engineered Foods Act.
ENVIRONMENTAL ISSUES SURROUNDING GE CROPS
The second major regulatory issue for new GE crops is ensuring that they do
not adversely affect the environment. For the federal regulatory system to
adequately carry out that function, the system must:
• ensure that all biotech products get a thorough environmental assessment
by a competent government agency before release into the environment;
and
• ensure that, if products are approved with conditions to manage possible
environmental risks, those conditions are adhered to (through compliance
assurance and enforcement measures).
Unfortunately, the current federal regulatory system for GE crops at the United
States Department of Agriculture (USDA) falls short on both accounts. 2
The Current Regulatory System at USDA Under the auspices of the Plant Pest
Act, the USDA has established a regulatory system for genetically engineered
plants that could become plant pests. Crops subject to those regulations include
(1) any crop that is a listed plant pest, and (2) any crop that has introduced
DNA from a listed plant pest or an organism whose plant-pest status is
2The focus here is on the USDA regulatory process for biotech crops and not EPA’s regulatory struc-
ture for plants engineered to contain a pesticide.
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undetermined. For example, the regulations capture any variety that was
genetically engineered using Agrobacterium DNA as a vector. The regulations
do␣ not include crops engineered using a gene gun, unless the inserted DNA
comes from a listed plant pest or an organism whose plant-pest status is
undetermined.
Any plant covered by USDA’s regulation must submit to one of three
oversight processes before release. The first is a notification, in which the
applicant provides details about its proposed release and the USDA has thirty
days to respond. The USDA has established criteria to determine which
products are eligible for the notification process and guidelines that must
be␣ met to minimize environmental effects from the release. Notification is
currently used to regulate virtually all of the field tests for GE crops under
USDA’s jurisdiction, and even for some crops that are grown commercially.
The second process is permitting, which requires a more detailed application
and a longer review time at USDA before the release is authorized. Genetically
engineered plants that must be permitted (instead of a notification) include
crops producing pharmaceuticals and those that could affect non-target
organisms. Permitting is not used as commonly as notification, although
hundreds of permits have been issued since USDA began regulating GE crops.
The third process is a petition for non-regulated status. A petition is a request
that USDA determine that there is no associated plant-pest risk and the crop no
longer needs to be regulated. A petition for non-regulated status has been the
primary pathway to commercialize GE crops. Before a petition is granted, USDA
conducts an environmental assessment of the crop and seeks input through a
formal public-comment period.
Inadequacies in USDA’s Current System There are numerous inadequacies in
USDA’s current method of regulating GE crops. First, the regulatory system
captures only GE crops that could become plant pests, whereas others, such as
those made with the gene gun and corn DNA, do not require even a notification
before release into the environment
Second, the USDA does not require a thorough environmental assessment
before a regulated GE crop is released. Crops released through either the
notification or the permitting process almost never receive an individual
environmental assessment, yet some of those crops might have a significant
impact on the environment. A recent report published by the National Research
Council (NRC) stated that, “With few exceptions, the environmental risks that
might accompany future novel plants cannot be predicted. Therefore, they
should be evaluated on a case-by-case basis.” Yet, notification and permitting
do␣ not evaluate environmental risks on a case-by-case basis since, in most
cases, no environmental assessment is conducted.
Third, for those crops that do receive an environmental assessment from
USDA (primarily for nonregulated status), those assessments are inadequate.
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According to the NRC report: “Currently, APHIS’s 3 environmental assessments
focus on the simplest ecological scale. . . . APHIS should include any impact on
regional farming practice or systems in its deregulation assessments.” Thus,
USDA’s environmental assessments do not address all relevant environmental
concerns.
Fourth, it is unclear whether USDA has the legal authority to adequately
address environmental issues that arise in an environmental assessment. USDA
has regulatory authority to address plant-pest risks, but does not have authority
to prevent a crop’s release if it may cause ecological damage unrelated to
agriculture.
Fifth, most large-scale releases occur after the GE crop has obtained
nonregulated status. Although the petition process for nonregulated status
is␣ transparent, open for public comment and involving an environmental
assessment, the process results in a crop that is no longer regulated by USDA.
That prevents USDA from requiring post-release monitoring for environmental
effects and from addressing unforeseen environmental issues. Therefore, for the
vast majority of crops, USDA has extremely limited ability to address
environmental issues that might arise after commercialization.
Finally, the process at USDA involves no food-safety analysis of the crop
before it is released into the environment. For open-pollinated crops such as
corn, a release could result in the gene-product entering the food chain. USDA’s
process makes no assessment of whether that gene product would be harmful to
humans if it were to enter the food supply.
Preventing Contamination of Other Crops and the Food Supply from Experimental
GE Crops and/or GE Crops Producing Non-food Products When the USDA
regulates a GE plant under either the notification or the permitting process,
one␣ of its goals is “to minimize persistence in the environment and inadvertent
mixing with ... products which are used for food or feed.” This is accomplished,
in part, by using containment and/or segregation procedures. Those procedures
may limit contamination, but do not eliminate it, since eliminating all
contamination is impossible.
The ability of the regulatory system to adequately contain GE plants that
might harm the environment or humans is extremely important, whether it is
a␣ corn plant producing a pharmaceutical or a sunflower plant producing an
industrial chemical. The USDA and FDA have stated they are working on
guidelines that will address contamination issues surrounding pharmaceutical
plants, but that guidance currently is not publicly available. Yet, numerous
field␣ trials and commercial planting of pharmaceutical crops have occurred
without uniform standards to minimize contamination. Consumers would lose
confidence in agricultural biotechnology and the safety of the food supply if
3Animal and Plant Health Inspection Service, a branch of the USDA.
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they found out that some food they are eating contained a pharmaceutical or
industrial chemical that has not been found safe to ingest. Thus, strong
regulatory structures that minimize contamination are important.
The first way to minimize the effects of GE crops on non-GE counterparts
and the food supply is through containment to limit gene flow. Containment
procedures include reproductive isolation measures, such as prescribed
distances for planting GE crops in areas where non-GE crops of the same
species are grown, planting guard rows between GE and non-GE crops, the use
of lines that shed sterile pollen, harvesting prior to flowering, netting or
bagging anthers prior to pollen shed, and the staggering of flowering times with
respect to adjacent crops.
For example, the USDA recently sent a letter to companies planning on
planting pharmaceutical corn crops in 2002, in which distance restrictions were
set forth, ranging from 0.25 to 5 miles (the latter being the distance from seed
corn) and planting times for the GE corn that are either 14 or 21 days before or
after adjacent non-GE corn. The letter, however, contained no scientific
justification for the distances or planting times chosen nor did it state how
effective the restrictions would be in reducing contamination of non-GE crops.
It is unclear whether those distances and planting times will reduce the chances
of gene flow by 50%, 90%, or 99%. Thus, although reproductive isolation is
necessary and needs to be established, there should be a public explanation as
to why certain procedures are required and what is the expected benefit.
The second type of containment procedure that minimizes persistence of
the␣ GE crop in the environment is in post-harvest activities, which includes
limiting the use of land for a period of time following the crop, monitoring the
land and neighboring fields for volunteer plants of the GE crop, and destroying
the crop after harvest using specific procedures. Those post-harvest restrictions
are important to prevent GE crops from persisting in the environment after field
trials or commercial plantings. It is unclear, however, how effective they are in
preventing gene transfer.
In addition to containment procedures, segregation is usually employed to
ensure that experimental GE crops and those producing non-food products
do␣ not mix with crops (both GE and conventional) that are grown for food.
Segregation has generally involved dedicated machinery and vehicles to harvest,
transport, and store certain GE crops.
Is segregation effective in preventing contamination? When farmers planted
StarLink™ corn that had been approved only for feed use, Aventis (the
developer) agreed that the crop would be segregated from corn used for human
consumption. StarLink™, however, ended up in the food supply, either because
no segregation system was actually in place or because it was ineffective. Many
experts now question whether any segregation system can effectively separate
one type of corn from another. Thus, it is an open question how effective
segregation can be at eliminating contamination of the food supply. If properly
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set up, segregation can minimize contamination, but may never be able to
eliminate it.
Enforcement When a GE crop has been approved for release, frequently the
approval sets forth conditions to minimize or eliminate environmental and/or
food-safety risks. It is imperative that developers and growers comply with
those conditions, and it is USDA’s job to verify adherence. Is the USDA doing
a␣ good job enforcing its conditional approvals? The answer is no.
The USDA has conducted some inspections of field trials and commercial
releases that have permits or submitted notifications, although the level of
effort is small compared to the universe of GE crops. To date, there have been
over 9,000 permitted releases or notifications for GE crops, of which only a
very small fraction has been inspected by USDA. The inspections USDA has
conducted have resulted in approximately sixty enforcement actions, primarily
letters explaining improper conduct and requesting adherence to restrictions.
When the USDA does inspect a permitted release, however, it is unclear
whether those inspections are as comprehensive as needed to safeguard the
environment. In particular, the USDA does not check to see if the containment
or segregation procedures are working. For example, inspectors do not check
neighboring fields to see if pollen has drifted to non-GE crops. Neither do they
test grains on the farm or on neighboring farms to ensure that the crop has been
properly segregated. Thus, the USDA should not only inspect to see if the
conditions imposed on a GE crop have been met; there is need to determine
whether those conditions resulted in containment and segregation.
Conclusions About USDA’s Regulation of GE Crops The USDA’s regulations do not
adequately protect the environment or humans from current GE crops and will
not adequately protect the environment and humans from the next generation
of crops, such as those producing pharmaceuticals. In particular, the USDA
regulatory system has the following deficiencies:
• it does not capture all GE crops;
• it does not result in a thorough environmental assessment of all GE crops;
• it does not have a mechanism for the monitoring of environmental
problems that might arise after a crop has obtained nonregulated status,
nor a means of enforcement if a problem occurs; and
• it does not conduct inspections to determine the effectiveness of
containment procedures to minimize gene flow from GE crops or of
segregation requirements to minimize food contamination from certain
GE␣ crops.
Until those deficiencies are eliminated, the federal government will not be
adequately ensuring that the only GE crops released are safe to humans and
the␣ environment.
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WHAT TO DO ABOUT GE CROPS THAT ARE NOT INTENDED TO BE
FOOD BUT MIGHT END UP IN THE FOOD SUPPLY?
As discussed earlier, the next generation of biotech food crops will provide non-
food products: pharmaceuticals, medical diagnostic proteins, etc. What would
happen if those crops accidentally ended up in the food supply due to gene
flow␣ from pollen, contamination of seed stock, or a breakdown in an identity-
preserved segregation system? Would they be safe to consume? Would they be
safe to consume only at certain exposure levels? Is there any authority for FDA
to review and approve those products as safe to eat in the event that they enter
the food supply? Those are all questions that need to be addressed. Contain-
ment and segregation will not be 100% effective, so it is only a matter of time
before one or more of the non-food GE crops enters the food chain.
The Federal Food Drug and Cosmetic Act (FFDCA) regulates everything that
is intended to be used as food or feed. A pharmaceutical corn plant or a corn
plant producing avidin, however, is not intended by the developer to be used as
food or feed. Thus, such products are neither food additives, nor would they be
subject to FDA’s voluntary notification process (or their proposed mandatory
notification rule). The FDA has limited authority over those products unless
they show up in food. At that stage, the FDA could consider foods containing
the pharmaceutical or industrial chemical as adulterated, and remove them
from the market. The burden would be on FDA, however, to prove that they are
adulterated.
The current system is not the best way to guarantee a safe food supply, when
contamination by non-food GE crops is inevitable. A possible solution to this
problem would be for the proposed mandatory FDA-approval process to apply
to non-food GE crops. Under that approval system, FDA could set tolerances
for non-food GE crops. Then, if that GE crop entered the food supply, eating
the engineered substance would be safe as long as the amount was below
the␣ tolerance level. No consumer would need to fear that they were eating
food␣ containing unsafe substances. In addition, the rigor of the food-safety
assessment conducted by FDA could be proportionate to the physical and
biological confinement of the crop. If the pharmaceutical plant is grown in a
location far from other corn plants, only a limited food-safety assessment might
be required because the likelihood of contamination would be extremely small.
On the other hand, if the pharmaceutical plant is grown in Iowa, a complete
food-safety analysis might be warranted.
CONCLUSION
Although agricultural biotechnology may allow us to produce more-nutritious
foods and useful medical products, the current federal regulatory structure is
not up to the task of guaranteeing that they are safe. With new legal authority
and better regulations, a strong, but not stifling, system can be established that
independently reviews products and approves those that are safe for consumers
and the environment. Such a system is essential if consumers are to have
confidence in biotechnology and accept its products in the marketplace.
